Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Sees Large Decrease in Short Interest

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the target of a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 10,000 shares, a drop of 30.1% from the August 15th total of 14,300 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average daily trading volume, of 39,700 shares, the days-to-cover ratio is presently 0.3 days.

Protagenic Therapeutics Stock Performance

NASDAQ PTIX traded down $0.08 during trading on Friday, hitting $0.79. The stock had a trading volume of 390,809 shares, compared to its average volume of 89,825. Protagenic Therapeutics has a 12 month low of $0.50 and a 12 month high of $1.98. The company’s 50-day moving average price is $0.70 and its two-hundred day moving average price is $1.08. The company has a market capitalization of $3.52 million, a PE ratio of -0.58 and a beta of 0.26.

Protagenic Therapeutics (NASDAQ:PTIX) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.36) EPS for the quarter.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.